ClinicalTrials.gg
RecruitingNCT06144164Updated Nov 10, 2026

A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer

A Phase 3 interventional study of Immediate Lymphatic Reconstruction and Volumetric arm measurements in Lymphedema, Lymphedema Arm and Lymphedema of Upper Arm, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 7 sites in United States. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
285
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 168 studies in Lymphedema with a site in United States — 37 open to participants now, 45 under way, 1 of them phase 3. Lymphedema · United States.

Planned enrollment
8th of 122
285 · median 50
Started
2023
with 6 others
Phase 3
4 of 168
1 open now
Primary completion
2030-03
later than 40 of 44 live
Registered
147th of 168
by date
Lead sponsor
9 of 168
Memorial Sloan Kettering Cancer Center

Among the 168 studies in Lymphedema with a site in United States, this one is the 8th largest by planned enrollment of the 122 interventional ones that give a count, is one of 7 that started in 2023, is one of 4 in phase 3, reaches primary completion later than 40 of the 44 other live ones, and was the 147th registered.

Lymphedema

529 studies on the registry are indexed under Lymphedema; 129 are open to participants now.

Browse Lymphedema studies →

Open to participants now

37 of the 168 studies in Lymphedema with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 84 Lymphedema studies recruiting now, 46 (55%) set no upper age limit and 21 (25%) stop at 75 or younger; 5 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 168 studies in Lymphedema with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study to test whether a comprehensive program may help the lymph fluid to drain out of the arm and prevent lymphedema in participants with breast cancer.

03

Conditions studied

  • Lymphedema
  • Lymphedema Arm
  • Lymphedema of Upper Arm
  • Breast Cancer
  • Breast Carcinoma
  • Female Breast Cancer

Keywords

  • immediate lymphatic reconstruction
  • axillary lymph node dissection
  • Lymphedema
  • Lymphedema Arm
  • Lymphedema of Upper Arm
  • Breast cancer
  • breast carcinoma
  • female breast cancer
  • Memorial Sloan Kettering Cancer Center
  • 23-303
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female sex
  • Diagnosis of breast cancer
  • Ages 18 to 75 years
  • Consented for unilateral ALND or for unilateral SLNB with possible ALND

Exclusion criteria

Exclusion Criteria:

  • Male sex
  • Does not speak English
  • Does not fit into study garment
  • Axillary recurrence
  • History of ALND
  • Requirement of bilateral ALND for the treatment of breast cancer
  • Treatment with SLNB only
  • Known anaphylactic allergy to ICG dye used in ILR
  • Impaired decision-making capacity
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
285 participants (estimated)

Study arms

  • Experimental
    Participants with Breast Cancer

    Participants will have a diagnosis of breast cancer and may undergo axillary lymph node dissection.

    Procedure: Immediate Lymphatic Reconstruction · Diagnostic Test: Volumetric arm measurements · Other: Lymphatic massage · Other: Range of motion exercises · Other: Compression garment use

Interventions

  • ProcedureImmediate Lymphatic Reconstruction

    Immediate Lymphatic Reconstruction will happen at the time of Axillary Lymph Node Dissection

    Also known as: ILR

  • Diagnostic testVolumetric arm measurements

    Volumetric arm measurements will occur at each in-person postoperative visit time points.

  • OtherLymphatic massage

    Participants will begin self-directed lymphatic massage 24 to 48 h after surgery and will continue to do lymphatic massage 3 times a week for 3 months after surgery or until 3 months after any adjuvant treatments (chemotherapy, radiation, etc.) are completed

  • OtherRange of motion exercises

    Participants will begin self-directed lymphatic massage 24 to 48 h after surgery and will continue to do lymphatic massage 3 times a week for 3 months after surgery or until 3 months after any adjuvant treatments (chemotherapy, radiation, etc.) are completed

  • OtherCompression garment use

    Participants will use compression garments 24 to 48 h after surgery and will continue daily use for at least 8 h a day for 3 months or until 3 months after any adjuvant treatments are completed

06

What researchers measure

Primary outcomes

  1. The difference between the baseline and postoperative arm volume measurement

    The primary objective is to determine the efficacy of a prevention program in decreasing the development of lymphedema in participants treated for breast cancer with Axillary Lymph Node Dissection/ALND by use of arm volume measurements. A ≥ 10% increase in RVC (arm volume difference between the affected and unaffected arms) between baseline and postoperative measures occurring at 12 months or later will indicate the development of lymphedema

    Time frame: Up to 24 months

07

Study locations

7 of 7 sites recruiting
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
    Basking Ridge, New Jersey 07920, United States
    Recruiting
    • Michelle Coriddi, MD · Contact646-608-8042
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
    Middletown, New Jersey 07748, United States
    Recruiting
    • Michelle Coriddi, MD · Contact646-608-8042
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities)
    Montvale, New Jersey 07645, United States
    Recruiting
    • Michelle Coriddi, MD · Contact646-608-8042
  • Memorial Sloan Kettering Commack (Limited Protocol Activities)
    Commack, New York 11725, United States
    Recruiting
    • Michelle Coriddi, MD · Contact646-608-8042
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities)
    Harrison, New York 10604, United States
    Recruiting
    • Michelle Coriddi, MD · Contact646-608-8042
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
    New York, New York 10065, United States
    Recruiting
    • Michelle Coriddi, MD · Contact646-608-8042
  • Memorial Sloan Kettering Nassau (Limited Protocol Activities)
    Uniondale, New York 11553, United States
    Recruiting
    • Michelle Coriddi, MD · Contact646-608-8042
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

Data sharing details ↗ · www.mskcc.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2023 (actual). Primary completion is estimated for Mar 2030, 76 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2023
First posted
Nov 22, 2023
StartActual
Nov 16, 2023
Primary completionEst.
Mar 16, 2030
CompletionEst.
Mar 16, 2030
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06144164
Responsible party
Sponsor
First posted
Nov 22, 2023
Start date
Nov 16, 2023
Primary completion
Mar 16, 2030 (estimated)
Completion
Mar 16, 2030 (estimated)
Last update
Nov 10, 2026

Study contacts

Michelle Coriddi, MD
Contact
coriddim@mskcc.org
646-608-8042
Babak Mahrara, MD
Contact
mehrarab@MSKCC.ORG
646-608-8085
Michelle Coriddi, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion